PMN · ProMIS Neurosciences Inc. Common Shares (ON)
View on chartInsiders & Stakes
| Jeremy M. Sclar 2012 Irrevocable Family Trust 10% Owner | ▼ Sell | Other | 3,710,459 Shares held | 7/25/2025 | View profile |
| Jeremy M. Sclar 10% Owner | ▼ Sell | Other | 3,710,459 Shares held | 7/25/2025 | View profile |
| Michael S. Gordon 10% Owner | ▼ Sell | Other | 2,435,029 Shares held | 7/25/2025 | View profile |
| 19 Promis Title 10% Owner | ▼ Sell | Other | 2,435,029 Shares held | 7/25/2025 | View profile |
| ABG Management Ltd. 10% Owner | ▲ Buy | Open Market | 943,090 Shares held | 2/3/2026 | View profile |
| Shafmaster Madge K. Director | ▲ Buy | Open Market | 208,333 Shares held | 9/24/2024 | View profile |
| Farfel Gail M Chief Executive Officer | ▲ Buy | Grant | 55,192 Shares held | 8/23/2023 | View profile |
| Eugene Williams Chairman and CEO | ▲ Buy | Open Market | 12,397 Shares held | 3/5/2026 | View profile |
| Max A. Milbury Principal Accounting Officer | ▲ Buy | Grant | 8,409 Shares held | 2/3/2026 | View profile |
| Johanne Kaplan Chief Development Officer | ▲ Buy | Open Market | 6,221 Shares held | 8/5/2026 | View profile |
| Neil K. Warma Chief Executive Officer | ▲ Buy | Grant | 6,183 Shares held | 2/3/2026 | View profile |
| Patrick D. Kirwin Director | ▲ Buy | Open Market | 4,653 Shares held | 4/22/2026 | View profile |
| Neil Cashman Chief Scientific Officer | ▲ Buy | Grant | 4,122 Shares held | 2/3/2026 | View profile |
| Malenfant Gavin T. Chief Operating Officer | ▲ Buy | Grant | 2,660 Shares held | 8/23/2023 | View profile |
Transaction History
| Johanne Kaplan | ▲ Buy | Open Market | 2,280 | $30K | 8/5/2026 |
| Patrick D. Kirwin | ▲ Buy | Open Market | 4,000 | $45K | 4/22/2026 |
| Eugene Williams | ▲ Buy | Open Market | 2,000 | $49K | 3/5/2026 |
| Eugene Williams | ▲ Buy | Open Market | 2,000 | $48K | 3/4/2026 |
| Eugene Williams | ▲ Buy | Open Market | 1,000 | $22K | 3/3/2026 |
| Eugene Williams | ▲ Buy | Open Market | 1,000 | $23K | 3/2/2026 |
| Johanne Kaplan | ▲ Buy | Open Market | 1,629 | $25K | 2/19/2026 |
| Max A. Milbury | ▲ Buy | Grant | 6,595 | $80K | 2/3/2026 |
| ABG Management Ltd. | ▲ Buy | Open Market | 700,741 | $8.5M | 2/3/2026 |
| Neil K. Warma | ▲ Buy | Grant | 6,183 | $75K | 2/3/2026 |
| Neil Cashman | ▲ Buy | Grant | 4,122 | $50K | 2/3/2026 |
| Johanne Kaplan | ▲ Buy | Grant | 2,060 | $25K | 2/3/2026 |
| Patrick D. Kirwin | ▲ Buy | Grant | 3,050 | $37K | 2/3/2026 |
| Max A. Milbury | ▲ Buy | Open Market | 30,392 | $15K | 10/3/2025 |
| Jeremy M. Sclar 2012 Irrevocable Family Trust | ▼ Sell | Other | 697,674 | — | 7/25/2025 |
| Jeremy M. Sclar 2012 Irrevocable Family Trust | ▼ Sell | Other | 697,674 | — | 7/25/2025 |
| Jeremy M. Sclar | ▼ Sell | Other | 697,674 | — | 7/25/2025 |
| Jeremy M. Sclar 2012 Irrevocable Family Trust | ▼ Sell | Other | 697,674 | — | 7/25/2025 |
| Jeremy M. Sclar | ▼ Sell | Other | 697,674 | — | 7/25/2025 |
| Jeremy M. Sclar | ▼ Sell | Other | 697,674 | — | 7/25/2025 |
| Michael S. Gordon | ▼ Sell | Other | 119,800 | — | 7/25/2025 |
| Michael S. Gordon | ▼ Sell | Other | 119,800 | — | 7/25/2025 |
| Michael S. Gordon | ▼ Sell | Other | 119,800 | — | 7/25/2025 |
| 19 Promis Title | ▼ Sell | Other | 119,800 | — | 7/25/2025 |
| 19 Promis Title | ▼ Sell | Other | 119,800 | — | 7/25/2025 |
| 19 Promis Title | ▼ Sell | Other | 119,800 | — | 7/25/2025 |
| Michael S. Gordon | ▼ Sell | Open Market | 93,223 | — | 6/30/2025 |
| Michael S. Gordon | ▼ Sell | Other | 48,333 | — | 3/13/2025 |
| Neil Cashman | ▲ Buy | Open Market | 15,000 | $15K | 2/10/2025 |
| Shafmaster Madge K. | ▲ Buy | Open Market | 70,000 | $91K | 9/24/2024 |
| Shafmaster Madge K. | ▲ Buy | Open Market | 70,000 | $90K | 9/23/2024 |
| Shafmaster Madge K. | ▲ Buy | Open Market | 60,000 | $75K | 9/20/2024 |
| Michael S. Gordon | ▲ Buy | Open Market | 16,292 | $23K | 9/17/2024 |
| Michael S. Gordon | ▲ Buy | Open Market | 76,931 | $94K | 9/16/2024 |
| Patrick D. Kirwin | ▲ Buy | Open Market | 10,000 | $12K | 8/14/2024 |
| 19 Promis Title | ▲ Buy | Open Market | 465,116 | — | 7/31/2024 |
| 19 Promis Title | ▼ Sell | Other | 500,000 | — | 7/31/2024 |
| Michael S. Gordon | ▲ Buy | Open Market | 465,116 | — | 7/31/2024 |
| Michael S. Gordon | ▼ Sell | Other | 500,000 | — | 7/31/2024 |
| Jeremy M. Sclar | ▲ Buy | Open Market | 697,674 | — | 7/31/2024 |
| Jeremy M. Sclar | ▼ Sell | Other | 150,000 | — | 7/31/2024 |
| Jeremy M. Sclar | ▼ Sell | Other | 150,000 | — | 7/31/2024 |
| Malenfant Gavin T. | ▲ Buy | Grant | 2,660 | — | 8/23/2023 |
| Farfel Gail M | ▲ Buy | Grant | 53,192 | — | 8/23/2023 |
| Patrick D. Kirwin | ▲ Buy | Grant | 11,000 | — | 8/23/2023 |
| Neil Cashman | ▲ Buy | Grant | 10,643 | — | 8/23/2023 |
| Max A. Milbury | ▲ Buy | Grant | 13,297 | — | 8/23/2023 |
| Eugene Williams | ▲ Buy | Open Market | 1,000 | $5K | 12/16/2022 |
| Eugene Williams | ▲ Buy | Open Market | 1,000 | $5K | 12/16/2022 |
| Patrick D. Kirwin | ▲ Buy | Open Market | 2,000 | $9K | 12/15/2022 |
| Farfel Gail M | ▲ Buy | Open Market | 1,000 | $5K | 12/14/2022 |
| Patrick D. Kirwin | ▲ Buy | Open Market | 1,000 | $5K | 12/13/2022 |
| Eugene Williams | ▲ Buy | Open Market | 1,000 | $5K | 12/12/2022 |
| Patrick D. Kirwin | ▲ Buy | Open Market | 1,000 | $5K | 12/9/2022 |
| Eugene Williams | ▲ Buy | Open Market | 1,000 | $5K | 12/7/2022 |
| Farfel Gail M | ▲ Buy | Open Market | 1,000 | $6K | 12/6/2022 |
| Eugene Williams | ▲ Buy | Open Market | 1,000 | $6K | 12/2/2022 |
| Patrick D. Kirwin | ▲ Buy | Open Market | 4,000 | $24K | 8/17/2022 |
| Eugene Williams | ▲ Buy | Open Market | 1,000 | $10K | 7/11/2022 |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
ProMIS Neurosciences Names Dr. Rubino as Chief Commercial Officer
ProMIS Neurosciences announced that Dr. Ivana Rubino, a veteran in Alzheimer’s and neuroscience, will serve as Chief Commercial Officer. Her experience is expected to strengthen the company’s commercial strategy and support product development. The move comes as the company seeks to advance its pipeline and expand market reach.
ProMIS Neurosciences Names Dr. Rubino as Chief Commercial Officer. ProMIS Neurosciences announced that Dr. Ivana Rubino, a veteran in Alzheimer’s and neuroscience, will serve as Chief Commercial Officer. Her experience is expected to strengthen the company’s commercial strategy and support product development. The move comes as the company seeks to advance its pipeline and expand market reach.